Memphis producer Tay Keith, 29, died in June after an overdose involving ketamine and mitragynine, the primary alkaloid associated with kratom, according to reported findings from the Nashville Medical Examiner’s Office. The findings also listed nicotine and ethanol in his system, alongside mild coronary artery disease, as contributing factors.
The death is a profound loss for a producer whose credits include work with Drake, Travis Scott, Eminem and Lil Baby. It also brings attention to mitragynine and the unsettled public-health debate around kratom: a plant-derived product that can be sold openly in much of the United States while remaining subject to growing scrutiny from lawmakers and health authorities.
Police conducted a welfare check at Keith’s Nashville apartment, where he was found with drug paraphernalia. No foul play was suspected. It remains unclear whether he knowingly used kratom or how mitragynine entered his system. The reported medical findings establish its presence, but they do not answer that separate question.
What the findings say—and what they do not
A toxicology finding is an important part of a medical examiner’s determination, but it should not be flattened into a simple one-substance narrative. In this case, the reported cause involved a combination of ketamine and mitragynine. Nicotine, ethanol and mild coronary artery disease were also noted as contributors.
That distinction matters. A multi-substance overdose means the risks cannot responsibly be assigned to one ingredient in isolation. It also means speculation about intent, dosage, product source or a person’s private circumstances goes beyond the information available. The most grounded takeaway is that the reported combination proved fatal.
Ketamine is a dissociative drug, a term used for substances that can alter perception and a person’s sense of connection to their surroundings. Mitragynine is an alkaloid, meaning a naturally occurring chemical compound found in a plant. In kratom, it is the principal compound discussed in the reported findings.
The source material describes mitragynine as binding to opioid receptors in the brain. An opioid receptor is a biological docking point involved in how the body and brain respond to opioid-type substances. This receptor activity is central to concern around kratom products: mitragynine can be associated with sedation, respiratory depression, physical dependence and withdrawal symptoms.
Respiratory depression means breathing becomes slowed or insufficient. It is one of the gravest hazards associated with substances that suppress the body’s central functions. When multiple substances are involved, the situation can become less predictable, which is why treating an overdose as a casual or routine risk is deeply dangerous.
Kratom’s unusual place in the marketplace
Kratom comes from a Southeast Asian plant, but its modern American retail footprint is a major part of this story. Products are sold in places such as gas stations, smoke shops and convenience stores, and may be presented as natural supplements or as products related to pain relief. Federal legality of the natural leaf does not make every product harmless, medically validated or equally regulated.
That disconnect between availability and perceived risk has helped make kratom difficult to discuss clearly. A product that appears beside ordinary convenience goods can seem familiar or low-stakes. Yet the active compound at issue in this case has opioid-receptor activity and can produce dependence-related effects. Some medical professionals have used the phrase “gas station heroin” to underline their concern about products that are easily purchased but may carry severe risks.
The phrase is deliberately provocative, and it should not replace precise discussion. Kratom is not simply interchangeable with heroin, nor does a retail setting reveal a product’s effect, concentration or safety. But the underlying warning is important: “natural” is a description of origin, not a guarantee of low risk.
There is also a difference between the plant material and newer, more potent products or compounds that can circulate under the broader kratom label. The supplied information notes that 7-OH, described as a synthetic and more potent version, has been temporarily scheduled as a controlled substance because of its potency and overdose risk. That makes careful terminology essential. “Kratom” can be used casually as an umbrella term, while the legal and medical picture may differ based on the precise compound or formulation involved.
A regulatory debate that is becoming more urgent
Tennessee reportedly enacted a full kratom ban in 2026 following legislative debate centered on the substance’s dangers and reputation. Other states are considering comparable action. Meanwhile, federal authorities have monitored kratom for years, even though the natural leaf has not been federally controlled.
This creates a patchwork environment in which a substance’s status can vary by location and by formulation. For consumers, that is not merely a legal technicality. It can blur the line between what is easily available, what is permitted and what carries serious health consequences. Those are three different questions.
Advocates have argued that kratom could have legitimate applications connected to opioid dependency. The public-health concerns cited in the current debate, however, include dependence, withdrawal, sedation, respiratory depression and overdose risk. Those positions are not resolved by marketing language, anecdote or a product’s point of sale. They are the competing issues legislators are confronting as they weigh restrictions.
Keith’s reported death does not settle that larger policy dispute on its own. What it does show is why the discussion cannot stay abstract. Mitragynine is not just a chemistry term or a line on a store shelf; it was listed in a fatal combination in the medical examiner’s reported account of this case.
Why care is needed in discussing a musician’s death
There is a temptation, particularly when an artist has a major catalogue and an unexpectedly public death, to turn a toxicology report into a complete biography. That would be unfair. Professional success does not make someone immune to substance-related danger, but it also does not explain a death. The known facts here are limited and should remain separate from assumptions about Keith’s life, work or intent.
His legacy as a producer deserves to be discussed on its own terms, apart from the circumstances of his death. So does the work now being done in his name: his family has established the Tay Keith Foundation to support music education and addiction awareness in Memphis.
That combination of purposes is significant. Music education gives young people access to a creative discipline and a possible professional path. Addiction awareness makes room for direct conversation about risks that can otherwise hide behind vague labels, convenience-store packaging or the misleading reassurance that a product is plant-based.
The music business also has a broader digital context in which names, reputations and work can be mishandled after they enter public circulation. For a different but related look at how artist identities can be exploited online, see our report on fake tracks being attached to real artists’ streaming pages.
The practical public-health lesson
The clearest lesson from the reported findings is not to presume safety from a product’s presentation. A plant-derived compound can still act on opioid receptors. A product sold in a familiar retail setting can still carry dependence and overdose concerns. And combinations of substances can be especially hazardous.
It is equally important not to use this tragedy to spread unsupported claims. The available account does not establish whether Keith intentionally used kratom, the form in which mitragynine was encountered, or the circumstances leading to the fatal combination. Those unknowns should remain unknown rather than being filled with online conjecture.
What is documented is grave enough: a 29-year-old producer died, and mitragynine was among the substances identified in a fatal overdose involving ketamine. As Tennessee moves to prohibit kratom and other jurisdictions consider their own response, the case adds a human dimension to a debate often framed around regulation, retail access and chemical terminology.
